Trials / Completed
CompletedNCT00266344
MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
MK0928 Phase IIb Dose-range Finding Study -Primary Insomnia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 520 (planned)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0928, gaboxadol / Duration of Treatment 3 Weeks | |
| DRUG | Placebo / Duration of Treatment 3 Weeks |
Timeline
- Start date
- 2005-11-01
- Completion
- 2006-10-01
- First posted
- 2005-12-16
- Last updated
- 2015-01-14
Source: ClinicalTrials.gov record NCT00266344. Inclusion in this directory is not an endorsement.